Beardsworth Selects OmniComm Systems TrialMaster Solution for the EDC of a Phase II Vaccine Study


Fort Lauderdale, FL

OmniComm Systems, Inc. announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm’s TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects.

"After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider,” said Michael J. O’Brien, Beardsworth President and CEO.

OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC utilizing OmniComm’s native, template matching, subsystem. Electronic exports from TrialMaster EDC to Beardsworth’s BNet portal will be achieved utilizing OmniComm’s new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.